CXCR4 and neoplasm: In future studies, it is imperative to obtain tumor biopsies to confirm the hypothesis that CXCR4 inhibition is associated with increased T cell trafficking to the tumor microenvironment, and further evaluate 40 mg dose as the appropriate dose to accomplish this task.